Propafenone efficacy in treatment of atrial fibrillation paroxysms: a placebo-controlled study

In a placebo-controlled study, propafenone efficacy and safety for pharmaceutical cardioversion in atrial fibrillation (AF) paroxysms were studied. The study included 50 patients aged 28-69 years (mean age 53,9+9,7), with AF paroxysms lasting for less than 48 hours. Participants were randomized to p...

Full description

Bibliographic Details
Published in:	Российский кардиологический журнал
Main Authors:	Yu. A. Bunin, L. K. Anfalova
Format:	Article
Language:	Russian
Published:	«FIRMA «SILICEA» LLC 2005-12-01
Subjects:	atrial fibrillation cardioversion propafenone
Online Access:	https://russjcardiol.elpub.ru/jour/article/view/2343

Similar Items

Comparison of efficacy of pharmacological cardioversion with antazoline and propafenone versus electrical cardioversion in atrial fibrillation during cryoablation
by: Konrad Klocek, et al.
Published: (2024-03-01)

Propafenone efficacy in paroxysmal atrial fibrillation
by: V. V. Skibitsky, et al.
Published: (2004-12-01)

Propafenone efficacy and safety in restoring and maintaining sinus rhythm in patients with recurrent atrial fibrillation: results of the open, prospective placebo-controlled trial
by: I. G. Fomina, et al.
Published: (2005-04-01)

Endothelial function changes in paroxysmal atrial fibrillation and treatment with propafenone
by: V. I. Podzolkov, et al.
Published: (2018-08-01)

Propafenone and amiodarone efficacy in paroxysmal atrial fibrillation treatment
by: N. N. Isakova, et al.
Published: (2006-06-01)

Pharmacological cardioversion of atrial fibrillation paroxysm in elderly and senile patients at prehospital stage
by: Andrei V. Syrov
Published: (2021-03-01)

Propafenone in restoring sinus rhythm among patients with persistent atrial fibrillation. PROMETEY – an open, multicenter, pilot study performed in the Russian Federation
by: I. G. Fomina, et al.
Published: (2005-08-01)

ANTIARRHYTHMIC EFFICACY OF PROPAFENONE IN PATIENTS WITH PERSISTENT ATRIAL FIBRILLATION
by: R. D. Kurbanov, et al.
Published: (2016-01-01)

Comparative Effectiveness of Aksaritmin and Propafenone in the Prevention of Atrial Fibrillation
by: Husniddin Sh. Kuchkarov, et al.
Published: (2023-06-01)

POSSIBLE PREDICTORS OF ATRIAL FIBRILLATION RECURRENCE IN LONG-TERM PROPHYLACTIC PROPAFENONE THERAPY
by: R. D. Kurbanov, et al.
Published: (2015-12-01)

EFFICACY AND SAFETY OF SINUS RHYTHM RESTORATION WITH AMIODARONE AND PROPAFENONE IN OUTPATIENTS, ECONOMIC ASPECTS (BASED ON DATA OF N.A. SEMASHKO NORTHERN MEDICAL CLINICAL CENTER)
by: T. A. Istomina, et al.
Published: (2016-01-01)

Medical therapy with flecainide and propafenone in atrial fibrillation: Long-term clinical experience in the tertiary care setting
by: Boldizsar Kovacs, et al.
Published: (2023-02-01)

Propafenone effect on inotropic myocardial function in patients with recurrent atral fibrillation
by: I. G. Fomina, et al.
Published: (2006-06-01)

Propafenone and lisinopril therapy effectiveness for sinus rhythm maintenance in patients with persistent atrial fibrillation and arterial hypertension (PROMETEY-III)
by: R. G. Oganov, et al.
Published: (1970-01-01)

PHARMACOEPIDEMIOLOGICAL ANALYSIS OF THE TREATMENT OF PAROXYSMAL AND PERSISTENT ATRIAL FIBRILLATION IN EVERY DAY CLINICAL PRACTICE
by: I. V. Graifer, et al.
Published: (2016-01-01)

Paroxysmal atrial fibrillation: treatment choice
by: B. A. Tatarsky
Published: (2007-06-01)

EFFECTIVENESS AND SAFETY OF PROPAFENONE (PROPANORM®) AND AMIODARONE (CORDARONE®) IN PATIENTS WITH ATRIAL FIBRILLATION, ARTERIAL HYPERTENSION, CORONARY HEART DISEASE, AND CHRONIC HEART FAILURE WITH INTACT LEFT VENTRICULAR SYSTOLIC FUNCTION
by: O. N. Miller, et al.
Published: (2010-08-01)

Propafenone in restoring sinus rhythm among patients with persistent atrial fibrillation. PROMETEY – an open, multicenter, pilot study performed in the Russian Federation (part II)
by: I. G. Fomina, et al.
Published: (2005-10-01)

PAROXYSMAL ATRIAL FIBRILLATION: CHOICE OF CARDIOVERSION THERAPY
by: B. A. Tatarskii
Published: (2015-12-01)

Clinical efficacy of potassium canreonate-canrenone in sinus rhythm restoration among patients with atrial fibrillation - a protocol of a pilot, randomized, double -blind, placebo-controlled study (CANREN-AF trial)
by: Rafał Dąbrowski, et al.
Published: (2020-05-01)

Indications for propafenone in the latest ESC guidelines and beyond
by: Krisztián Kássa, et al.
Published: (2025-08-01)

Methods of sinus rhythm restoration in patients with persistent and long-standing persistent atrial fibrillation
by: L. M. Kalmanson, et al.
Published: (2025-06-01)

Present and future of antiarrhythmic therapy for atrial fibrillation: A review
by: Aida I. Tarzimanova
Published: (2024-11-01)

Acute Management of Paroxysmal Atrial Fibrillation with Intravenous Flecainide plus Oral Beta-Blockers
by: Athanasios Kartalis, et al.
Published: (2024-06-01)

Biomarkers of Atrial Fibrillation Recurrence in Patients with Paroxysmal or Persistent Atrial Fibrillation Following External Direct Current Electrical Cardioversion
by: Ozan Demirel, et al.
Published: (2023-05-01)

THE PROPANORM EFFICACY IN RAPID RELIEF OF SYMPTOMS OF PAROXYSMAL AURICULAR FIBRILLATION
by: N. N. Borovkov, et al.
Published: (2003-10-01)

Frequency of cardioversions as an additional risk factor for stroke in atrial fibrillation – the FinCV-4 study
by: Samuli Jaakkola, et al.
Published: (2022-12-01)

INFLUENCE OF METABOLIC THERAPY ON LIFE QUALITY IN PATIENTS WITH ATRIAL FIBRILLATION PAROXYSMS
by: I.M. Fushtey, et al.
Published: (2022-09-01)

CARDIOVERSION WITH BI- AND MONOPHASE DEFIBRILLATORS IN PATIENTS WITH PAROXYSMAL ATRIAL FIBRILLATION
by: V. A. Lusov, et al.
Published: (2010-02-01)

Aggressive Rhythm Control Strategy in Atrial Fibrillation Patients Presenting at the Emergency Department: The HEROMEDICUS Study Design and Initial Results
by: Dimitrios Tsiachris, et al.
Published: (2024-03-01)

Efficiency of Electrical Cardioversion of Paroxysmal Atrial Fibrillation in the Use of Bipolar QuasiSinusoidal Impulse in Patients with Coronary Heart Disease
by: V. A. Vostrikov, et al.
Published: (2014-06-01)

Intravenous Cavutilide for Pharmacological Conversion of Paroxysmal and Persistent Atrial Fibrillation in Patients with Heart Failure
by: Maria M. Beliaeva, et al.
Published: (2023-12-01)

Effectiveness of Class IC Antiarrhythmics in Patients with Paroxysmal Form of Atrial Fibrillation in Absence of Structural Heart Disease
by: D. A. Tsaregorodtsev, et al.
Published: (2023-05-01)

MR-proANP, sST2, BNP and sinus rhythm maintenance 1 year after electrical cardioversion for atrial fibrillation
by: Marc Badoz, et al.
Published: (2025-08-01)

Prevalence and risk factors associated with decompensated heart failure after successful elective cardioversion for atrial fibrillation and atrial flutter
by: Christina Healy, et al.
Published: (2024-11-01)

Prevention of atrial fibrillation episodes in patients with chronic heart failure: a new approach to the old problem
by: Yu. M. Pozdnyakov, et al.
Published: (1970-01-01)

Predictors of time to conversion of new‐onset atrial fibrillation to sinus rhythm with amiodarone therapy
by: Ihsan Dursun, et al.
Published: (2020-08-01)

Serial electrical cardioversion for refractory atrial fibrillation with rapid ventricular response post ablation
by: Katherine Liu, et al.
Published: (2025-10-01)

Cardioversion of atrial fibrillation does not affect obstructive sleep apnea
by: Niklas Höglund, et al.
Published: (2017-04-01)

Atrial fibrillation: real-life experience of a rhythm control with electrical cardioversion in a community hospital
by: Artemiy Okhotin, et al.
Published: (2024-04-01)